RealRate

PHARMACEUTICAL 2019

Q32 Bio Inc
Rank 110 of 361

HOMOLOGY Medicines, Inc.



PHARMACEUTICAL 2019

Q32 Bio Inc
Rank 110 of 361

The relative strengths and weaknesses of Q32 Bio Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Q32 Bio Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 83% points.The greatest weakness of Q32 Bio Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 320%, being 71% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	221,685
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	25,433
Liabilities, Non-Current	0
Other Assets	1,772
Other Compr. Net Income	-4.0
Other Expenses	0
Other Liabilities	38,944
Other Net Income	4,349
Other Revenues	3,684
Property and Equipment	35,637
Research and Development	47,948
Selling, General and Administrative Expense	17,300

Output Variable	Value in 1000 USD
Assets	259,094
Liabilities	64,377
Expenses	65,248
Revenues	3,684
Stockholders Equity	194,717
Net Income	-57,215
Comprehensive Net Income	-57,217
BaseVar	198,378
ECR before LimitedLiability	227%
Economic Capital Ratio	320%